About Semaglutide
Semaglutide is a 31-amino-acid GLP-1 analog with a fatty-acid side chain that extends its half-life to 7 days. Produces 14.9% weight loss at 68 weeks in the STEP-1 trial at 2.4 mg weekly.
Reported benefits
- Drives 14.9% weight loss at 68 weeks (STEP-1)
- Reduces appetite within 72 hours of first dose
- Once-weekly subcutaneous dosing
Research citations
- Wilding et al. 2021 - NEJM (STEP-1)
- Davies et al. 2021 - Lancet
How Semaglutide fits the category
Semaglutide sits inside the Best Peptides for Weight Loss category. For the full ranking and head-to-head comparisons, read Best Peptides for Weight Loss.

